Minimally invasive gastrectomy for gastric adenocarcinoma in the United States: Utilization and short‐term oncologic outcomes. Issue 6 (23rd September 2015)
- Record Type:
- Journal Article
- Title:
- Minimally invasive gastrectomy for gastric adenocarcinoma in the United States: Utilization and short‐term oncologic outcomes. Issue 6 (23rd September 2015)
- Main Title:
- Minimally invasive gastrectomy for gastric adenocarcinoma in the United States: Utilization and short‐term oncologic outcomes
- Authors:
- Ecker, Brett L.
Datta, Jashodeep
McMillan, Matthew T.
Poe, Sarah‐Lucy C.
Drebin, Jeffrey A.
Fraker, Douglas L.
Dempsey, Daniel T.
Karakousis, Giorgos C.
Roses, Robert E. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24052-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>When performed at select centers, minimally invasive gastrectomy (MIG) for gastric adenocarcinoma is associated with reduced perioperative morbidity, and similar oncologic outcomes as compared to open gastrectomy (OG). Utilization of, and outcomes associated with, MIG in the United States have not been characterized.</p> </sec> <sec id="jso24052-sec-0002" sec-type="section"> <title>Methods</title> <p>The National Cancer Database (2010–2011) was queried for AJCC pStage IB‐IIIC patients who underwent curative‐intent OG (n = 2, 303) or MIG (n = 331). Multivariable models identified factors associated with MIG utilization, R0 resection rates, and adequate lymph node staging (LNS).</p> </sec> <sec id="jso24052-sec-0003" sec-type="section"> <title>Results</title> <p>MIG was more frequently utilized for T1/T2 (<italic>P</italic> &lt; 0.001), N0 (<italic>P</italic> = 0.022), and stage IB (<italic>P </italic>= 0.001) tumors. MIG was associated with shorter hospital stay (<italic>P</italic> &lt; 0.001), equivalent lymph node examination (<italic>P </italic>= 0.337) and superior rates of R0 resection (<italic>P </italic>= 0.011) compared with OG. In patients undergoing MIG, R0 resection was associated with performance of near‐total/total gastrectomy (OR 3.90, 95%CI 1.10–13.9) and tumors &lt; 5 cm<abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso24052-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>When performed at select centers, minimally invasive gastrectomy (MIG) for gastric adenocarcinoma is associated with reduced perioperative morbidity, and similar oncologic outcomes as compared to open gastrectomy (OG). Utilization of, and outcomes associated with, MIG in the United States have not been characterized.</p> </sec> <sec id="jso24052-sec-0002" sec-type="section"> <title>Methods</title> <p>The National Cancer Database (2010–2011) was queried for AJCC pStage IB‐IIIC patients who underwent curative‐intent OG (n = 2, 303) or MIG (n = 331). Multivariable models identified factors associated with MIG utilization, R0 resection rates, and adequate lymph node staging (LNS).</p> </sec> <sec id="jso24052-sec-0003" sec-type="section"> <title>Results</title> <p>MIG was more frequently utilized for T1/T2 (<italic>P</italic> &lt; 0.001), N0 (<italic>P</italic> = 0.022), and stage IB (<italic>P </italic>= 0.001) tumors. MIG was associated with shorter hospital stay (<italic>P</italic> &lt; 0.001), equivalent lymph node examination (<italic>P </italic>= 0.337) and superior rates of R0 resection (<italic>P </italic>= 0.011) compared with OG. In patients undergoing MIG, R0 resection was associated with performance of near‐total/total gastrectomy (OR 3.90, 95%CI 1.10–13.9) and tumors &lt; 5 cm (OR 2.78, 95%CI 1.07–7.26). Adequate LNS was associated with surgery at academic (OR 1.99, 95%CI 1.19–3.32) or high‐volume facilities (OR 2.97, 95%CI 1.59–5.54), tumor size ≥ 5 cm (OR 1.85, 95%CI 1.10–3.11), and node positivity (OR 1.75, 95%CI 1.04–2.93).</p> </sec> <sec id="jso24052-sec-0004" sec-type="section"> <title>Conclusions</title> <p>MIG is selectively utilized in cases with favorable tumor characteristics. In such cases, short‐term oncologic outcomes are equivalent to those achieved with OG. Worse oncologic outcomes in specific subgroups underscore opportunities for quality improvement. <italic>J. Surg. Oncol. 2015;112:616–621</italic>. © 2015 Wiley Periodicals, Inc.</p> </sec> </abstract> … (more)
- Is Part Of:
- Journal of surgical oncology. Volume 112:Issue 6(2015:Nov. 01)
- Journal:
- Journal of surgical oncology
- Issue:
- Volume 112:Issue 6(2015:Nov. 01)
- Issue Display:
- Volume 112, Issue 6 (2015)
- Year:
- 2015
- Volume:
- 112
- Issue:
- 6
- Issue Sort Value:
- 2015-0112-0006-0000
- Page Start:
- 616
- Page End:
- 621
- Publication Date:
- 2015-09-23
- Subjects:
- Cancer -- Surgery -- Periodicals
Neoplasms -- Periodicals
616 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1096-9098 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/jso.24052 ↗
- Languages:
- English
- ISSNs:
- 0022-4790
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5067.380000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3542.xml